Immatics Biotechnologies Gmbh Stock Performance
| IMTXW Stock | USD 0.41 0.01 2.38% |
The company retains a Market Volatility (i.e., Beta) of 2.0, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immatics Biotechnologies will likely underperform. At this point, Immatics Biotechnologies has a negative expected return of -2.2%. Please make sure to check out Immatics Biotechnologies' treynor ratio and the relationship between the skewness and day typical price , to decide if Immatics Biotechnologies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days immatics biotechnologies GmbH has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
1 | Cantor Fitzgerald Forecasts Higher Earnings for Immatics - MarketBeat | 11/22/2024 |
| Begin Period Cash Flow | 148.5 M |
Immatics |
Immatics Biotechnologies Relative Risk vs. Return Landscape
If you would invest 224.00 in immatics biotechnologies GmbH on August 28, 2024 and sell it today you would lose (182.00) from holding immatics biotechnologies GmbH or give up 81.25% of portfolio value over 90 days. immatics biotechnologies GmbH is currently producing negative expected returns and takes up 10.6496% volatility of returns over 90 trading days. Put another way, 94% of traded stocks are less volatile than Immatics, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Immatics Biotechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immatics Biotechnologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as immatics biotechnologies GmbH, and traders can use it to determine the average amount a Immatics Biotechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2069
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMTXW |
Estimated Market Risk
| 10.65 actual daily | 94 94% of assets are less volatile |
Expected Return
| -2.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immatics Biotechnologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immatics Biotechnologies by adding Immatics Biotechnologies to a well-diversified portfolio.
Immatics Biotechnologies Fundamentals Growth
Immatics Stock prices reflect investors' perceptions of the future prospects and financial health of Immatics Biotechnologies, and Immatics Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immatics Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.42) % | ||||
| Revenue | 54 M | ||||
| EBITDA | (88.93 M) | ||||
| Net Income | (96.99 M) | ||||
| Total Debt | 15.4 M | ||||
| Book Value Per Share | 2.66 X | ||||
| Cash Flow From Operations | 18.23 M | ||||
| Market Capitalization | 673 M | ||||
| Total Asset | 509.96 M | ||||
| Retained Earnings | (597.29 M) | ||||
| Working Capital | 292.82 M | ||||
About Immatics Biotechnologies Performance
Evaluating Immatics Biotechnologies' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immatics Biotechnologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immatics Biotechnologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.43) | (0.45) |
Things to note about Immatics Biotechnologies performance evaluation
Checking the ongoing alerts about Immatics Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immatics Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immatics Biotechnologies generated a negative expected return over the last 90 days | |
| Immatics Biotechnologies has high historical volatility and very poor performance | |
| Immatics Biotechnologies has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 54 M. Net Loss for the year was (96.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Latest headline from news.google.com: Cantor Fitzgerald Forecasts Higher Earnings for Immatics - MarketBeat |
- Analyzing Immatics Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immatics Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Immatics Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immatics Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immatics Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immatics Biotechnologies' stock. These opinions can provide insight into Immatics Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.